BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 27003232)

  • 1. Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction.
    Han SW; Choi SW; Ryu KH; Kim HJ; Kim SH; Shim WJ; Cha TJ; Choi DJ; Kim YJ; Yoo BS; Kim JH; Hwang KK; Jeon H; Shin MS
    Cardiovasc Ther; 2016 Jun; 34(3):172-9. PubMed ID: 27003232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study.
    Lee HY; Chung WJ; Jeon HK; Seo HS; Choi DJ; Jeon ES; Kim JJ; Shin JH; Kang SM; Lim SC; Baek SH
    Korean J Intern Med; 2016 Mar; 31(2):277-87. PubMed ID: 26879662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical, hemodynamic and neurohumoral effects of switching patients with chronic heart failure from not recommended -adrenoblockers to bisoprolol in ambulatory practice].
    Ageev FT; Zhubrina ES; Ovchinnikov AG; Seredenina EM
    Kardiologiia; 2010; 50(6):41-7. PubMed ID: 20659026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutoff values of NT-proBNP for the prediction of low functional capacity, decreased ejection fraction and cardiovascular events in patients with heart failure.
    Koç M; Bozkurt A; Yildiray-Sahin D; Unal I; Acartürk E
    Cardiol J; 2009; 16(1):43-9. PubMed ID: 19130415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
    Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ivabradine therapy on heart failure biomarkers.
    Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
    Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.
    Fischer-Rasokat U; Honold J; Lochmann D; Wolter S; Liebetrau C; Fichtlscherer S; Möllmann H; Spyridopoulos I; Hamm CW
    Clin Res Cardiol; 2016 Jun; 105(6):527-34. PubMed ID: 26687495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure].
    Wang F; Xu ZM; Wang L; Bian WY; Jia X; Duan B; Li W; Li YS
    Zhonghua Nei Ke Za Zhi; 2005 Jul; 44(7):490-4. PubMed ID: 16080835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
    Kusunose K; Imai T; Tanaka A; Dohi K; Shiina K; Yamada T; Kida K; Eguchi K; Teragawa H; Takeishi Y; Ohte N; Yamada H; Sata M; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):186. PubMed ID: 34521417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.
    Sabbah HN; Gupta RC; Kohli S; Wang M; Hachem S; Zhang K
    Circ Heart Fail; 2016 Feb; 9(2):e002206. PubMed ID: 26839394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-terminal prohormone brain natriuretic peptide plasma levels in heart failure are affected both directly and indirectly by carvedilol.
    Kallistratos MS; Dritsas A; Laoutaris ID; Cokkinos DV
    Angiology; 2008; 59(3):323-8. PubMed ID: 18388105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction.
    Kubánek M; Goode KM; Lánská V; Clark AL; Cleland JG
    Eur J Heart Fail; 2009 Apr; 11(4):367-77. PubMed ID: 19179406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure.
    van de Ven LL; van Veldhuisen DJ; Goulder M; Zilahi Z; Meyer WR; Willenheimer R
    Int J Cardiol; 2010 Sep; 144(1):59-63. PubMed ID: 19481278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study.
    Hori M; Nagai R; Izumi T; Matsuzaki M
    Heart Vessels; 2014 Mar; 29(2):238-47. PubMed ID: 23559359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of N-terminal pro-type-B natriuretic peptide and Doppler left ventricular diastolic variables in patients with chronic systolic heart failure stabilized by therapy.
    Dini FL; Conti U; Fontanive P; Andreini D; Panicucci E; De Tommasi SM
    Am J Cardiol; 2008 Aug; 102(4):463-8. PubMed ID: 18678307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial.
    Edelmann F; Musial-Bright L; Gelbrich G; Trippel T; Radenovic S; Wachter R; Inkrot S; Loncar G; Tahirovic E; Celic V; Veskovic J; Zdravkovic M; Lainscak M; Apostolović S; Neskovic AN; Pieske B; Düngen HD;
    JACC Heart Fail; 2016 Feb; 4(2):140-149. PubMed ID: 26682793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of heart rate recovery in patients with heart failure or left ventricular systolic dysfunction.
    Lipinski MJ; Vetrovec GW; Gorelik D; Froelicher VF
    J Card Fail; 2005 Oct; 11(8):624-30. PubMed ID: 16230267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal-probrain natriuretic peptide and echocardiography in patients with systolic heart failure.
    Al-Meslmani BM; Fahoum SK; Shamia MG
    Saudi Med J; 2005 Nov; 26(11):1695-8. PubMed ID: 16311650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.